EHR Alert for Heart Disease
(CACTUS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Doctors are testing a new tool called EchoNext to see if it can help find heart problems earlier. EchoNext looks at the heart's electrical test, called an ECG, and uses artificial intelligence (AI) to check for signs of structural heart disease (SHD). SHD includes conditions like weak heart pumping, heart valve problems, or extra thickening of the heart muscle. These problems are common but often go undiagnosed until they cause serious issues like heart failure or stroke.
The main questions this study will answer are:
Can EchoNext alerts help emergency doctors find hidden heart problems sooner?
Does this lead to more follow-up heart tests, like an echocardiogram (heart ultrasound)?
What this means for patients: If a person has an ECG in the Emergency Department, the EchoNext tool may be used to check their heart. If the tool finds something unusual, their doctor may receive an alert and may then recommend further heart tests or follow-up care.
This study will help researchers learn if using EchoNext improves early diagnosis and treatment of heart disease.
Who Is on the Research Team?
Pierre Elias, MD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
This trial is for adults who come to the Emergency Department and have an ECG done. It focuses on people who might have hidden heart problems like weak heart pumping or valve issues, but does not specify other inclusion or exclusion criteria.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Trial Overview
The study is testing if using EchoNext, an AI tool that analyzes ECGs and sends alerts to doctors about possible structural heart disease, helps find these conditions earlier compared to usual care.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Emergency department providers will be alerted in the electronic health record (EHR) if a patient's electrocardiogram (ECG) ordered in the ED is identified by the EchoNext algorithm as suggesting structural heart disease (SHD) and potentially benefit from an echocardiogram. These patients will also be referred to Community Tele-paramedicine for follow-up for potential echocardiogram.
Emergency department providers will not be alerted in the electronic health record (EHR) if a patient's electrocardiogram (ECG) ordered in the ED is identified by the EchoNext algorithm as suggesting structural heart disease (SHD) and potentially benefit from an echocardiogram.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pierre Elias
Lead Sponsor
Edwards Lifesciences
Industry Sponsor
Todd Brinton
Edwards Lifesciences
Chief Medical Officer since 2023
MD from Stanford University
Bernard Zovighian
Edwards Lifesciences
Chief Executive Officer since 2023
MBA from INSEAD
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.